<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEVOTHYROXINE SODIUM- levothyroxine sodium anhydrous injection, powder, lyophilized, for solution </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Levothyroxine Sodium for Injection safely and effectively.  See full prescribing information for Levothyroxine Sodium for Injection.  
<br><br>
Levothyroxine Sodium for Injection
<br>
Initial U.S. Approval: 1969</div>
<div class="Warning">
<div>
<h1 class="Warning">
<span class="Bold"><span class="Emphasis">WARNING: NOT FOR TREATMENT OF <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">OBESITY</span> OR FOR </span></span><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">WEIGHT LOSS</span></span></span> 
</h1>
<span class="Bold"><span class="Emphasis">Thyroid hormones, including </span></span><span class="Bold"><span class="Emphasis">Levothyroxine Sodium for Injection</span></span><span class="Bold"><span class="Emphasis">, should not be used for the treatment of <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> or for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. (<a href="#c28f026a-36b1-4a38-8eb2-b798394fee69">5.3</a>)  <br>
Larger doses may produce serious or even life threatening manifestations of toxicity. (<a href="#eb69a74f-31dc-466d-975d-e520deb810a6">6</a>)      </span></span><br><br>
</div>
<div></div>
</div>
<div></div>
<div class="Warning">
<div>
<h1 class="Warning">
<span class="Bold"><span class="Emphasis">WARNING: NOT FOR TREATMENT OF <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">OBESITY</span> OR FOR </span></span><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">WEIGHT LOSS</span></span></span> 
</h1>
<span class="Bold"><span class="Emphasis">Thyroid hormones, including </span></span><span class="Bold"><span class="Emphasis">Levothyroxine Sodium for Injection</span></span><span class="Bold"><span class="Emphasis">, should not be used for the treatment of <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> or for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. (<a href="#c28f026a-36b1-4a38-8eb2-b798394fee69">5.3</a>)  <br>
Larger doses may produce serious or even life threatening manifestations of toxicity. (<a href="#eb69a74f-31dc-466d-975d-e520deb810a6">6</a>)      </span></span><br><br>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Levothyroxine Sodium is an L-thyroxine product. Levothyroxine (T<span class="Sub">4</span>) Sodium for Injection is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4059416" conceptname="Myxedema coma">myxedema coma</span>. <span class="Bold"><span class="Emphasis">(<a href="#c6b93fea-ffef-43df-9c35-d339338ec3b9">1</a>)</span></span> </p>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">Important Limitations of Use:</span></span> </p>
<p class="Highlighta">The relative bioavailability of this drug has not been established. Use caution when converting patients from oral to intravenous levothyroxine. </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>An initial intravenous loading dose of Levothyroxine Sodium for Injection between 300 to 500 mcg followed by once daily intravenous maintenance doses between 50 and 100 mcg should be administered, as clinically indicated, until the patient can tolerate oral therapy.  (<span class="Bold"><span class="Emphasis"><a href="#b704b0d7-70cf-4762-8bb9-8a4f7da7dca3">2.1</a></span></span>)</li>
<li>Reconstitute the lyophilized Levothyroxine Sodium for Injection by aseptically adding 5 mL of 0.9% Sodium Chloride Injection, USP. Shake vial to ensure complete mixing. Reconstituted drug product is preservative free. Use immediately after reconstitution. Discard any unused portion. (<span class="Bold"><span class="Emphasis"><a href="#c30c456e-aba1-45ef-b3a2-1661208a39f3">2.3</a></span></span>)</li>
<li>Do not add to other IV fluids. (<span class="Bold"><span class="Emphasis"><a href="#c30c456e-aba1-45ef-b3a2-1661208a39f3">2.3</a></span></span>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Lyophilized powder for injection in single use vials: 100 mcg, 200 mcg and 500 mcg. (<span class="Bold"><span class="Emphasis"><a href="#c98f7851-bf09-483d-b9b4-529fd6fe747a">3</a></span></span>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None.  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Excessive bolus doses of Levothyroxine Sodium for Injection (&gt; 500 mcg) are associated with cardiac complications, particularly in the elderly and in patients with an underlying cardiac condition. Initiate therapy with doses at the lower end of the recommended range. (<span class="Bold"><span class="Emphasis"><a href="#d696a2c7-626a-4eca-aad9-d29049610b13">5.1</a></span></span>)</li>
<li>Close observation of the patient following the administration of Levothyroxine Sodium for Injection is advised. (<span class="Bold"><span class="Emphasis"><a href="#d696a2c7-626a-4eca-aad9-d29049610b13">5.1</a></span></span>)</li>
<li>Levothyroxine Sodium for Injection therapy for patients with previously undiagnosed <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">endocrine disorders</span>, including <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4254542" conceptname="Hypopituitarism">hypopituitarism</span>, and <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span>, may worsen symptoms of these endocrinopathies. (<span class="Bold"><span class="Emphasis"><a href="#b782dff6-8328-417d-9a87-c17c5ae3815f">5.2</a></span></span>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Excessive doses of L-thyroxine can predispose to signs and symptoms compatible with <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>.    (<a href="#section-6">6</a>)</p>
<p class="Highlighta">   (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC, Medical Affairs Department at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></span>  (<a href="#section-6">6</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Many drugs affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium for Injection. (<span class="Bold"><span class="Emphasis"><a href="#c1d9df17-7bb7-4c7c-a9d7-9e6239cd3f6d">7</a></span></span>, <span class="Bold"><span class="Emphasis"><a href="#e3bfe820-fed8-4540-b4a3-9b31a8214ea3">12.3</a></span></span>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>Elderly and those with underlying cardiovascular disease should receive doses at the lower end of the recommended range. (<span class="Bold"><span class="Emphasis"><a href="#c858e7cd-539b-4da1-bddd-9304fd0c155b">8.5</a></span></span>)</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsRevision">Revised: 12/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h2><a href="#section-1.1" class="toc">WARNING: NOT FOR TREATMENT OF <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">OBESITY</span> OR FOR <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">WEIGHT LOSS</span></a></h2>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosing in the Elderly and in Patients with Cardiovascular Disease<br></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Reconstitution Directions<br></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Risk of Cardiac Complications in Elderly and in Patients with Cardiovascular Disease<br></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Need for Concomitant Glucocorticoids and Monitoring for Other Diseases in Patients with <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span><br></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Not Indicated for Treatment of <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span><br></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Antidiabetic Therapy<br></a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Oral Anticoagulants<br></a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Digitalis Glycosides<br></a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Antidepressant Therapy<br></a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Ketamine<br></a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Sympathomimetics<br></a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Drug-Laboratory Test Interactions<br></a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use and Patients with Underlying Cardiovascular Disease<br></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and Pharmacology<br></a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied<br></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="bf485c24-2496-4d04-a775-bc040b424a4f"></a><a name="section-1"></a><p></p>
<h1></h1>
<br><div class="Section" data-sectionCode="43685-7">
<a name="cfa4a0f9-8ce0-45ca-94bd-6faf680be196"></a><a name="section-1.1"></a><p></p>
<h2>WARNING: NOT FOR TREATMENT OF <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">OBESITY</span> OR FOR <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">WEIGHT LOSS</span></h2>
<span class="Bold"><span class="Emphasis">Thyroid hormones, including </span></span><span class="Bold"><span class="Emphasis">Levothyroxine Sodium for Injection</span></span><span class="Bold"><span class="Emphasis">, should not be used for the treatment of <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> or for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. (<a href="#c28f026a-36b1-4a38-8eb2-b798394fee69">5.3</a>)  <br>
Larger doses may produce serious or even life threatening manifestations of toxicity. (<a href="#eb69a74f-31dc-466d-975d-e520deb810a6">6</a>)</span></span><br>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="c6b93fea-ffef-43df-9c35-d339338ec3b9"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Levothyroxine Sodium for Injection is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4059416" conceptname="Myxedema coma">myxedema coma</span>. Important Limitations of Use: The relative bioavailability between Levothyroxine Sodium for Injection and oral levothyroxine products has not been established.  Caution should be used when switching patients from oral levothyroxine products to Levothyroxine Sodium for Injection as accurate dosing conversion has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dfcfc32b-c13f-4147-a147-73c239c45cec"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="b704b0d7-70cf-4762-8bb9-8a4f7da7dca3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage</h2>
<p class="First">An initial intravenous loading dose of Levothyroxine Sodium for Injection between 300 to 500 mcg, followed by once daily intravenous maintenance doses between 50 and 100 mcg, should be administered, as clinically indicated, until the patient can tolerate oral therapy.  The age, general physical condition, cardiac risk factors, and clinical severity of <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span> and duration of <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span> symptoms should be considered when determining the starting and maintenance dosages of Levothyroxine Sodium for Injection.</p>
<p>Levothyroxine Sodium for Injection produces a gradual increase in the circulating concentrations of the hormone with an approximate half-life of 9 to 10 days in hypothyroid patients.  Daily administration of Levothyroxine Sodium for Injection should be maintained until the patient is capable of tolerating an oral dose and is clinically stable.  For chronic treatment of <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, an oral dosage form of levothyroxine should be used to maintain a euthyroid state.  Relative bioavailability between Levothyroxine Sodium for Injection and oral levothyroxine products has not been established.  Based on medical practice, the relative bioavailability between oral and intravenous administration of Levothyroxine Sodium for Injection is estimated to be from 48 to 74%.  Due to differences in absorption characteristics of patients and the oral levothyroxine product formulations, TSH and thyroid hormone levels should be measured a few weeks after initiating oral levothyroxine and dose adjusted accordingly.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b4cb3007-03d5-4008-8670-b1cf9088c37c"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosing in the Elderly and in Patients with Cardiovascular Disease<br>
</h2>
<p class="First">Intravenous levothyroxine may be associated with cardiac toxicity—including <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, or worsening of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> and death—in the elderly and in those with underlying cardiovascular disease.  Therefore, cautious use, including doses in the lower end of the recommended range, may be warranted in these populations.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="c30c456e-aba1-45ef-b3a2-1661208a39f3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Reconstitution Directions<br>
</h2>
<p class="First">Reconstitute the lyophilized Levothyroxine Sodium for Injection by aseptically adding 5 mL of 0.9% Sodium Chloride Injection, USP only.  Shake vial to ensure complete mixing. The resultant solution will have a final concentration of approximately 20 mcg per mL, 40 mcg per mL and  and 100 mcg per mL for the 100 mcg, 200 mcg and 500 mcg vials, respectively.  Reconstituted drug product is preservative free and is stable for 4 hours.  Discard any unused portion.  DO NOT ADD LEVOTHYROXINE SODIUM FOR INJECTION TO OTHER IV FLUIDS.  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="c98f7851-bf09-483d-b9b4-529fd6fe747a"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Levothyroxine Sodium for Injection is supplied as a lyophilized powder at three strengths in single use amber-colored vials: 100 mcg, 200 mcg and 500 mcg. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="b94deae2-f43d-459d-9da7-a25f41e19a39"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="e3fb0346-5aeb-44ff-8e2d-408c68ee5a7b"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="d696a2c7-626a-4eca-aad9-d29049610b13"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Risk of Cardiac Complications in Elderly and in Patients with Cardiovascular Disease<br>
</h2>
<p class="First">Excessive bolus dosing of Levothyroxine Sodium for Injection (greater than 500 mcg) are associated with cardiac complications, particularly in the elderly and in patients with an underlying cardiac condition.  Adverse events that can potentially be related to the administration of large doses of Levothyroxine Sodium for Injection include <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, or worsening of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Cautious use, including doses in the lower end of the recommended range, may be warranted in these populations.  Close observation of the patient following the administration of Levothyroxine Sodium for Injection is advised. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="b782dff6-8328-417d-9a87-c17c5ae3815f"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Need for Concomitant Glucocorticoids and Monitoring for Other Diseases in Patients with <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span><br>
</h2>
<p class="First">Occasionally, chronic <span class="product-label-link" type="condition" conceptid="135215" conceptname="Hashimoto thyroiditis">autoimmune thyroiditis</span>, which can lead to <span class="product-label-link" type="condition" conceptid="4059416" conceptname="Myxedema coma">myxedema coma</span>, may occur in association with other <span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">autoimmune disorders</span> such as <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span>, and insulin‑dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.  Patients should be treated with replacement glucocorticoids prior to initiation of treatment with Levothyroxine Sodium for Injection, until adrenal function has been adequately assessed.  Failure to do so may precipitate an acute <span class="product-label-link" type="condition" conceptid="4088744" conceptname="Severe adrenal insufficiency">adrenal crisis</span> when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone.  With initiation of Levothyroxine Sodium for Injection, patients with <span class="product-label-link" type="condition" conceptid="4059416" conceptname="Myxedema coma">myxedema coma</span> should also be monitored for previously undiagnosed <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span>. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="c28f026a-36b1-4a38-8eb2-b798394fee69"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Not Indicated for Treatment of <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span><br>
</h2>
<p class="First">Thyroid hormones, including Levothyroxine Sodium for Injection, either alone or with other therapeutic agents, should not be used for the treatment of <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> or for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.  In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.  Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> effects <span class="Italics"><span class="Emphasis">[see Adverse Reactions (<a href="#eb69a74f-31dc-466d-975d-e520deb810a6">6</a>) and Overdosage (<a href="#bcda84b4-e1af-47c4-8a17-9fc44a27969c">10</a>)].</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="eb69a74f-31dc-466d-975d-e520deb810a6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Excessive doses of levothyroxine can predispose to signs and symptoms compatible with <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>.  The signs and symptoms of <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> include, but are not limited to: <span class="product-label-link" type="condition" conceptid="138717" conceptname="Toxic diffuse goiter">exophthalmic goiter</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, increased pulse and blood pressure, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, heat intolerance, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and menstrual irregularities. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="c1d9df17-7bb7-4c7c-a9d7-9e6239cd3f6d"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Many drugs affect thyroid hormone pharmacokinetics and metabolism (e.g., synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium for Injection.  In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs (see Section <a href="#e3bfe820-fed8-4540-b4a3-9b31a8214ea3">12.3</a>). </p>
<div class="Section" data-sectionCode="34073-7">
<a name="cf43332a-ab08-493b-a484-c72977aa141e"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Antidiabetic Therapy<br>
</h2>
<p class="First">Addition of levothyroxine to antidiabetic or insulin therapy may result in increased antidiabetic agent or insulin requirements.  Careful monitoring of diabetic control is recommended, especially when thyroid therapy is started, changed, or discontinued.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="cfb5bdec-7316-4688-9a4b-4b091915e7fc"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Oral Anticoagulants<br>
</h2>
<p class="First">Levothyroxine increases the response to oral anticoagulant therapy.  Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the Levothyroxine Sodium for Injection dose is increased.  <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time should be closely monitored to permit appropriate and timely dosage adjustments.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="d54f7f54-98f5-497d-9a13-e4f18495e3f4"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Digitalis Glycosides<br>
</h2>
<p class="First">The therapeutic effects of digitalis glycosides may be reduced by levothyroxine.  Serum digitalis glycoside levels may be decreased when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ea77e25b-e6c3-405d-822b-3af0d89f4dc7"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Antidepressant Therapy<br>
</h2>
<p class="First">Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines.  Toxic effects may include increased risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> and CNS stimulation; onset of action of tricyclics may be accelerated. Administration of sertraline in patients stabilized on levothyroxine may result in increased levothyroxine requirements.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="a0150bad-423d-471b-bde2-8071d8c793a8"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Ketamine<br>
</h2>
<p class="First">Concurrent use may produce marked <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; cautious administration to patients receiving thyroid hormone therapy is recommended.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ab2aca05-49ef-4624-97b0-13cbbe1f3e65"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Sympathomimetics<br>
</h2>
<p class="First">Concurrent use may increase the effects of sympathomimetics or thyroid hormone.  Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="e2753e7d-f1bc-4c05-81a1-f3c20d57d702"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Drug-Laboratory Test Interactions<br>
</h2>
<p class="First">Changes in thyroxine binding globulin (TBG) concentration must be considered when interpreting levothyroxine and triiodothyronine values, which necessitates measurement and evaluation of unbound (free) hormone and/or determination of the free levothyroxine index. Pregnancy, <span class="product-label-link" type="condition" conceptid="4223947" conceptname="Viral hepatitis, type A">infectious hepatitis</span>, estrogens, estrogen containing oral contraceptives, and <span class="product-label-link" type="condition" conceptid="4120604" conceptname="Acute intermittent porphyria">acute intermittent porphyria</span> increase TBG concentrations.  Decreases in TBG concentrations are observed in <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, severe <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>, severe liver disease, <span class="product-label-link" type="condition" conceptid="4253197" conceptname="Acromegaly">acromegaly</span>, and after androgen or corticosteroid therapy.  Familial hyper or hypo thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="a2371cc3-d59e-4d08-8a9d-50d18ceba759"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="c92214a9-3929-40f9-9131-c5d97b91a7d5"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Pregnancy Category A</span></span> – There are no reported cases of Levothyroxine Sodium for Injection used to treat <span class="product-label-link" type="condition" conceptid="4059416" conceptname="Myxedema coma">myxedema coma</span> in patients who were pregnant or lactating.  Studies in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not shown an increased risk of fetal abnormalities.  Therefore, pregnant patients who develop <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span> should be treated with Levothyroxine Sodium for Injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus. </p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ee44e315-3405-45e2-9eab-9df7e7832a97"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">Patients in labor who develop <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span> have not been reported in the literature.  However, patients should be treated with Levothyroxine Sodium for Injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="bac718b0-0589-43c9-a856-9311c141c469"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Adequate replacement doses of thyroid hormones are required to maintain normal lactation.  There are no reported cases of Levothyroxine Sodium for Injection used to treat <span class="product-label-link" type="condition" conceptid="4059416" conceptname="Myxedema coma">myxedema coma</span> in patients who are lactating.  However, such patients should be treated with Levothyroxine Sodium for Injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the nursing patient.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="eecd097b-46a8-4004-aadb-f0e3f5facbe6"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4059416" conceptname="Myxedema coma">Myxedema coma</span> is a disease of the elderly.  An approved, oral dosage form of levothyroxine should be used in the pediatric patient population for maintaining a euthyroid state in non-complicated <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="c858e7cd-539b-4da1-bddd-9304fd0c155b"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use and Patients with Underlying Cardiovascular Disease<br>
</h2>
<p class="First">See Section 2, <a href="#dfcfc32b-c13f-4147-a147-73c239c45cec">Dosage and Administration</a>, for full prescribing information in the geriatric patient population.  Because of the increased prevalence of cardiovascular disease in the elderly, cautious use of Levothyroxine Sodium for Injection in the elderly and in patients with known cardiac risk factors is advised.  <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span> is a common side effect associated with levothyroxine treatment in the elderly <span class="Italics"><span class="Emphasis">[see Dosage and Administration (<a href="#dfcfc32b-c13f-4147-a147-73c239c45cec">2</a></span></span><span class="Italics"><span class="Emphasis">) and Warnings and Precautions (<a href="#e3fb0346-5aeb-44ff-8e2d-408c68ee5a7b">5</a></span></span><span class="Italics"><span class="Emphasis">)].</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="bcda84b4-e1af-47c4-8a17-9fc44a27969c"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In general, the signs and symptoms of overdosage with levothyroxine are those of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> <span class="Italics"><span class="Emphasis">[see Warnings and Precautions (<a href="#e3fb0346-5aeb-44ff-8e2d-408c68ee5a7b">5</a></span></span><span class="Italics"><span class="Emphasis">) and Adverse Reactions (<a href="#eb69a74f-31dc-466d-975d-e520deb810a6">6</a></span></span><span class="Italics"><span class="Emphasis">)].  </span></span>In addition, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> may occur.  <span class="product-label-link" type="condition" conceptid="375557" conceptname="Cerebral embolism">Cerebral embolism</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported.  Excessive doses of Levothyroxine Sodium for Injection (greater than 500 mcg) are associated with cardiac complications in patients with underlying cardiac disease.</p>
<p><span class="Bold"><span class="Emphasis">Treatment of Overdosage</span></span></p>
<p>Levothyroxine Sodium for Injection should be reduced in dose or temporarily discontinued if signs or symptoms of overdosage occur.  To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good resource is the certified Regional Poison Control Center.  In managing overdosage, consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, interaction among drugs, and unusual drug kinetics in the patient.</p>
<p>In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, appropriate supportive treatment should be initiated as dictated by the patient’s medical status.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="b36b0064-5e0a-4d69-9af3-6638da326657"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Levothyroxine Sodium for Injection contains synthetic crystalline levothyroxine (L-thyroxine) sodium salt.  Levothyroxine sodium has an empirical formula of C<span class="Sub">15</span>H<span class="Sub">10</span>I<span class="Sub">4</span>NNaO<span class="Sub">4</span>, a molecular weight of 798.85 g/mol (anhydrous), and the following structural formula:</p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce990712-49c1-4f66-9ee4-c770e8ec394c&amp;name=levothyroxine-sodium-for-injection-figure-1-levothy-stru.jpg"> </p>
<p> </p>
<p>Levothyroxine Sodium for Injection is a sterile, preservative-free lyophilized powder consisting of the active ingredient, levothyroxine sodium, and the excipients dibasic sodium phosphate heptahydrate, USP; mannitol, USP; and sodium hydroxide, NF in single-use amber glass vials.  Levothyroxine Sodium for Injection is available at three dosage strengths: 100 mcg per vial, 200 mcg per vial and 500 mcg per vial.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="e35ed810-4167-4332-a871-22a4cf7396ad"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="c14d8b25-894a-452a-956f-4f64e9143782"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis.  Triiodothyronine (T<span class="Sub">3</span>) and levothyroxine (T<span class="Sub">4</span>) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA.  This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.</p>
<p>The physiological actions of thyroid hormones are produced predominantly by T<span class="Sub">3</span>, the majority of which (approximately 80%) is derived from T<span class="Sub">4</span> by deiodination in peripheral tissues.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="a923d6ae-6a16-48fc-9176-9fb3df9ea3a5"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Thyroid hormone synthesis and secretion is regulated by the hypothalamic pituitary-thyroid axis.  Thyrotropin releasing hormone (TRH) released from the hypothalamus stimulates secretion of thyrotropin stimulating hormone (TSH) from the anterior pituitary.  TSH, in turn, is the physiologic stimulus for the synthesis and secretion of thyroid hormones, T<span class="Sub">4</span> and T<span class="Sub">3</span>, by the thyroid gland.  Circulating serum T<span class="Sub">3</span> and T<span class="Sub">4</span> levels exert a feedback effect on both TRH and TSH secretion.  When serum T<span class="Sub">3</span> and T<span class="Sub">4</span> levels increase, TRH and TSH secretion decrease. When thyroid hormone levels decrease, TRH and TSH secretion increases.  TSH is used for the diagnosis of <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> and evaluation of levothyroxine therapy adequacy with other laboratory and clinical data <span class="Italics"><span class="Emphasis">[see Dosage (<a href="#b704b0d7-70cf-4762-8bb9-8a4f7da7dca3">2.1</a>)].</span></span>   There are drugs known to affect thyroid hormones and TSH by various mechanisms and those examples are diazepam, ethioamide, lovastatin, metoclopramide, 6-mercaptopurine, nitroprusside, perphenazine, and thiazide diuretics.  Some drugs may cause a transient decrease in TSH secretion without <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> and those drugs (dose) are dopamine (greater than 1 mcg per kg per min), glucocorticoids (hydrocortisone greater than 100 mg per day or equivalent) and octreotide (greater than 100 mcg per day).</p>
<p>Thyroid hormones regulate multiple metabolic processes and play an essential role in normal growth and development, and normal maturation of the central nervous system and bone.  The metabolic actions of thyroid hormones include augmentation of cellular respiration and thermogenesis, as well as metabolism of proteins, carbohydrates and lipids.  The protein anabolic effects of thyroid hormones are essential to normal growth and development.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="e3bfe820-fed8-4540-b4a3-9b31a8214ea3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Absorption </span></span>– Levothyroxine Sodium for Injection is administered via the intravenous route.  Following administration, the synthetic levothyroxine cannot be distinguished from the natural hormone that is secreted endogenously.  </p>
<p><span class="Bold"><span class="Emphasis">Distribution –</span></span> Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine binding globulin (TBG), thyroxine binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone.  The higher affinity of both TBG and TBPA for T<span class="Sub">4</span> partially explains the higher serum levels, slower metabolic clearance, and longer half life of T<span class="Sub">4</span> compared to T<span class="Sub">3</span>.  Protein bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone.  Only unbound hormone is metabolically active.  Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins <span class="Italics"><span class="Emphasis">[see Warnings and Precautions (<a href="#e3fb0346-5aeb-44ff-8e2d-408c68ee5a7b">5</a>) and Drug Interactions (<a href="#c1d9df17-7bb7-4c7c-a9d7-9e6239cd3f6d">7</a>)].</span></span>   Thyroid hormones do not readily cross the placental barrier <span class="Italics"><span class="Emphasis">[see Warnings and Precautions (<a href="#e3fb0346-5aeb-44ff-8e2d-408c68ee5a7b">5</a>) and Use in Specific Populations (<a href="#a2371cc3-d59e-4d08-8a9d-50d18ceba759">8</a>)].</span></span></p>
<p><span class="Bold"><span class="Emphasis">Metabolism</span></span> – T<span class="Sub">4</span> is slowly eliminated.  The major pathway of thyroid hormone metabolism is through sequential deiodination.  Approximately eighty percent of circulating T<span class="Sub">3</span> is derived from peripheral T<span class="Sub">4</span> by monodeiodination.  The liver is the major site of degradation for both T<span class="Sub">4</span> and T<span class="Sub">3</span>, with T<span class="Sub">4</span> deiodination also occurring at a number of additional sites, including the kidney and other tissues.  Approximately 80% of the daily dose of T<span class="Sub">4</span> is deiodinated to yield equal amounts of T<span class="Sub">3</span> and reverse T<span class="Sub">3</span> (r T<span class="Sub">3</span>).  T<span class="Sub">3</span> and r T<span class="Sub">3</span> are further deiodinated to diiodothyronine.  Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.</p>
<p><span class="Bold"><span class="Emphasis">Elimination </span></span>– Thyroid hormones are primarily eliminated by the kidneys.  A portion of the conjugated hormone reaches the colon unchanged, where it is hydrolyzed and eliminated in feces as the free hormones.  Urinary excretion of T<span class="Sub">4</span> decreases with age.</p>
<p><span class="Bold"><span class="Emphasis">Table 1:</span></span> Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Hormone</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold"><span class="Emphasis">Ratio in </span></span></p>
<p><span class="Bold"><span class="Emphasis">Thyroglobulin </span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold"><span class="Emphasis">Biologic </span></span></p>
<p><span class="Bold"><span class="Emphasis">Potency</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold"><span class="Emphasis">Half-Life </span></span></p>
<p><span class="Bold"><span class="Emphasis">(Days)</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold"><span class="Emphasis">Protein </span></span></p>
<p><span class="Bold"><span class="Emphasis">Binding </span></span></p>
<p><span class="Bold"><span class="Emphasis">(%)<span class="Sup">2</span></span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><p class="First">T<span class="Sub">4</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10 to 20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6 to 8<span class="Sup">1</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">99.96</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><p class="First">T<span class="Sub">3</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">≤ 2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">99.5</p></td>
</tr>
</tbody></table>
<p>T<span class="Sub">4</span>:  Levothyroxine</p>
<p>T<span class="Sub">3</span>:  Liothyronine</p>
<p><span class="Sup">1</span> 3 to 4 days in <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, 9 to 10 days in <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.</p>
<p><span class="Sup">2</span> Includes TBG, TBPA, and TBA.</p>
<p><span class="Bold"><span class="Emphasis">Drug Interactions</span></span></p>
<p>A listing of drug interaction with T<span class="Sub">4</span> is provided in the following tables, although it may not be comprehensive due to the introduction of new drugs that interact with the thyroidal axis or the discovery of previously unknown interactions.  The prescriber should be aware of this fact and should consult appropriate reference sources (e.g., package inserts of newly approved drugs, medical literature) for additional information if a drug-drug interaction with levothyroxine is suspected.</p>
<p><span class="Bold"><span class="Emphasis">Table 2:</span></span> Drugs That May Alter T<span class="Sub">4</span> and T<span class="Sub">3</span> Serum Transport Without Affecting free T<span class="Sub">4</span> Concentration (Euthyroidism)</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Drugs That May Increase Serum TBG Concentration</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Drugs That May Decrease Serum TBG Concentration                                                                           <br></span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<p class="First">Clofibrate</p>
<p>Estrogen-containing oral contraceptives</p>
<p>Estrogens (oral)</p>
<p>Heroin / Methadone</p>
<p>5-Fluorouracil</p>
<p>Mitotane</p>
<p>Tamoxifen</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">Androgens</span> / Anabolic Steroids</p>
<p>Asparaginase</p>
<p>Glucocorticoids</p>
<p>Slow-Release Nicotinic Acid</p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="middle">
<p class="First"><span class="Bold"><span class="Emphasis">                                                                         Drugs That May Cause Protein-Binding Site Displacement</span></span></p>
<p>Potential impact<span class="Bold"><span class="Emphasis">:</span></span> Administration of these agents with levothyroxine results in an initial transient increase in FT<span class="Sub">4</span>.  Continued administration results in a decrease in serum T<span class="Sub">4</span> and normal FT<span class="Sub">4</span> and TSH concentrations and, therefore, patients are clinically euthyroid.</p>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Salicylates (&gt; 2 g/day)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Salicylates inhibit binding of T<span class="Sub">4</span> and T<span class="Sub">3</span> to TBG and transthyretin.  An initial increase in serum FT<span class="Sub">4</span> is followed by return of FT<span class="Sub">4</span> to normal levels with sustained therapeutic serum salicylate concentrations, although total-T<span class="Sub">4</span> levels may decrease by as much as 30%.</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<p class="First">Other drugs:</p>
<p>Furosemide (&gt; 80 mg IV)</p>
<p>Heparin </p>
<p>Hydantoins </p>
<p>Non-Steroidal Anti-inflammatory Drugs</p>
<p>- Fenamates</p>
<p>- Phenylbutazone</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"> </p></td>
</tr>
</tbody></table>
<p><span class="Bold"><span class="Emphasis">Table 3:</span></span>  Drugs That May Alter Hepatic Metabolism of T<span class="Sub">4</span> (<span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span>)</p>
<p>Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased levothyroxine requirements.</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Drug or Drug Class</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Carbamazepine</p>
<p>Hydantoins</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total- and free- T<span class="Sub">4</span> may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid.</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Other drugs:</p>
<p>Phenobarbital</p>
<p>Rifampin</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
</tr>
</tbody></table>
<p><span class="Bold"><span class="Emphasis">Table 4:</span></span>  Drugs That May Decrease Conversion of T<span class="Sub">4</span> to T<span class="Sub">3</span></p>
<p>Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T<span class="Sub">4</span> to T<span class="Sub">3</span>, leading to decreased T<span class="Sub">3</span> levels.  However, serum T<span class="Sub">4</span> levels are usually normal but may occasionally be slightly increased.</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Drug or Drug Class</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold"><span class="Emphasis">Effect</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<p class="First">Beta-adrenergic antagonists </p>
<p>(e.g. Propranolol &gt; 160 mg/day)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">In patients treated with large doses of propranolol (&gt; 160 mg/day), T<span class="Sub">3</span> and T<span class="Sub">4</span> levels change slightly, TSH levels remain normal, and patients are clinically euthyroid.  It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<p class="First">Glucocorticoids </p>
<p>(e.g. Dexamethasone <span class="Underline"><span class="Emphasis">&gt;</span></span> 4 mg/day)</p>
<p> </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First">Short-term administration of large doses of glucocorticoids may decrease serum T<span class="Sub">3</span> concentrations by 30% with minimal change in serum T<span class="Sub">4</span> levels.  However, long-term glucocorticoid therapy may result in slightly decreased T<span class="Sub">3</span> and T<span class="Sub">4</span> levels due to decreased TBG production (see above).</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<p class="First">Other drug:</p>
<p>Amiodarone</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><p class="First"> </p></td>
</tr>
</tbody></table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="a96dbddc-a2fe-4023-95e1-f194b9fe448c"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="a46bb69f-8ff6-4366-af30-4329c809b4f6"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Animal studies have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility of Levothyroxine Sodium for Injection. </p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="be463866-7ff9-4d3f-82ac-3c6ee8099d45"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and Pharmacology<br>
</h2>
<p class="First">No animal toxicology studies have been conducted with Levothyroxine Sodium for Injection.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="bed8e86a-30f9-468d-a537-f3890bd964fe"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">No clinical studies have been conducted with Levothyroxine Sodium for Injection in patients with <span class="product-label-link" type="condition" conceptid="4059416" conceptname="Myxedema coma">myxedema coma</span>.  However, data from published literature support the intravenous use of levothyroxine sodium for the treatment of <span class="product-label-link" type="condition" conceptid="4059416" conceptname="Myxedema coma">myxedema coma</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="c4ae6065-ecc7-44e5-adaa-87f56ec9ab6e"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="c8ac7907-5a25-4c2b-bdc2-cf5e94de4a58"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied<br>
</h2>
<p class="First">Levothyroxine Sodium for Injection is available in three dosage strengths.</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom">
<span class="Bold"><span class="Emphasis">Product </span></span><p class="First"><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom">
<span class="Bold"><span class="Emphasis">NDC </span></span><p class="First"><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><p class="First"><span class="Bold"><span class="Emphasis">Strength</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom">
<p class="First"><span class="Bold"><span class="Emphasis">Reconstituted</span></span></p>
<p><span class="Bold"><span class="Emphasis">Concentration</span></span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">506107    <br>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">63323-649-07    <br>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">100 mcg/vial     </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">20 mcg/mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" colspan="1" valign="top">506247 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" colspan="1" valign="top">63323-647-10 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" colspan="1" valign="top">200 mcg/vial <br>
</td>
<td class="Botrule Lrule Rrule Toprule" colspan="1" valign="top">40 mcg/mL <br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">506248   <br>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">63323-648-10 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">500 mcg/vial</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">100 mcg/mL</p></td>
</tr>
</tbody></table>
<br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="d42b59ad-37fd-4959-803a-105ae1d8766e"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage and Handling<br>
</h2>
<p class="First">Protect from light and store dry product at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].  Reconstituted drug product is preservative free.  Discard any unused portion.</p>
<p>This container closure is not made with natural rubber latex.</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="c4b08f81-13cb-40f6-ad5b-9c081b6d83d0"></a><a name="section-15"></a><p></p>
<h1></h1>
<div class="Figure"><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce990712-49c1-4f66-9ee4-c770e8ec394c&amp;name=levothyroxine-sodium-for-injection-figure-2-fklogo.jpg"></div>
<br><p class="First">451253C</p>
<p>Revised: April 2013</p>
<p>  </p>
<span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Levothyroxine 100 mcg Single Use Vial Label </span></span><p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-649-07</p>
<p>506107</p>
<p><span class="Bold"><span class="Emphasis">Levothyroxine Sodium for Injection</span></span></p>
<p><span class="Bold"><span class="Emphasis">100 mcg/vial</span></span></p>
<p>For Intravenous Use</p>
<p>Single Use Vial</p>
<p>Discard any unused portion.</p>
<p>Rx only</p>
<p> </p>
<p><img alt="506107-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce990712-49c1-4f66-9ee4-c770e8ec394c&amp;name=levothyroxine-sodium-for-injection-figure-3-506107-vial.jpg"> </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Levothyroxine 100 mcg Single Use Vial Carton Panel</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-649-07</p>
<p>506107</p>
<p><span class="Bold"><span class="Emphasis">Levothyroxine Sodium for Injection</span></span></p>
<p><span class="Bold"><span class="Emphasis">100 mcg/vial</span></span></p>
<p>For Intravenous Use</p>
<p>Single Use Vial</p>
<p>Discard any unused portion.</p>
<p>Rx only</p>
<p><img alt="506107-box" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce990712-49c1-4f66-9ee4-c770e8ec394c&amp;name=levothyroxine-sodium-for-injection-figure-4-506107-box.jpg"> </p>
<p> </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">P</span></span><span class="Bold"><span class="Emphasis">ACKAGE LABEL - PRINCIPAL DISPLAY - Levothyroxine 500 mcg Single Use Vial Label</span></span> </p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-648-10</p>
<p>506248</p>
<p><span class="Bold"><span class="Emphasis">Levothyroxine Sodium for Injection</span></span></p>
<p><span class="Bold"><span class="Emphasis">500 mcg/vial</span></span></p>
<p>For Intravenous Use</p>
<p>Single Use Vial</p>
<p>Discard any unused portion.</p>
<p>Rx only</p>
<p> </p>
<p><img alt="506248-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce990712-49c1-4f66-9ee4-c770e8ec394c&amp;name=levothyroxine-sodium-for-injection-figure-5-506248-vial.jpg"></p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">P</span></span><span class="Bold"><span class="Emphasis">ACKAGE LABEL - PRINCIPAL DISPLAY - Levothyroxine 500 mcg Single Use Vial Carton Panel</span></span> </p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-648-10</p>
<p>506248</p>
<p><span class="Bold"><span class="Emphasis">Levothyroxine Sodium for Injection</span></span></p>
<p><span class="Bold"><span class="Emphasis">500 mcg/vial</span></span></p>
<p>For Intravenous Use</p>
<p>Single Use Vial</p>
<p>Discard any unused portion.</p>
<p>Rx only</p>
<p> </p>
<p><img alt="506248-box" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce990712-49c1-4f66-9ee4-c770e8ec394c&amp;name=levothyroxine-sodium-for-injection-figure-6-506248-box.jpg"> </p>
<p><span class="Bold"><span class="Emphasis">P</span></span><span class="Bold"><span class="Emphasis">ACKAGE LABEL - PRINCIPAL DISPLAY - Levothyroxine 200 mcg Single Use Vial Label</span></span> </p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-647-10</p>
<p>506247</p>
<p><span class="Bold"><span class="Emphasis">Levothyroxine Sodium for Injection</span></span></p>
<p><span class="Bold"><span class="Emphasis">200 mcg/vial</span></span></p>
<p>For Intravenous Use</p>
<p>Single Use Vial</p>
<p>Discard any unused portion.</p>
<p>Rx only</p>
<p><img alt="506247-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce990712-49c1-4f66-9ee4-c770e8ec394c&amp;name=levothyroxine-sodium-for-injection-figure-7-506247-vial.jpg"></p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">P</span></span><span class="Bold"><span class="Emphasis">ACKAGE LABEL - PRINCIPAL DISPLAY - Levothyroxine 200 mcg Single Use Vial Carton Label</span></span> </p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-647-10</p>
<p>506247</p>
<p><span class="Bold"><span class="Emphasis">Levothyroxine Sodium for Injection</span></span></p>
<p><span class="Bold"><span class="Emphasis">200 mcg/vial</span></span></p>
<p>For Intravenous Use</p>
<p>Single Use Vial</p>
<p>Discard any unused portion.</p>
<p>Rx only</p>
<p><img alt="506247-box" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce990712-49c1-4f66-9ee4-c770e8ec394c&amp;name=levothyroxine-sodium-for-injection-figure-8-506247-box.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVOTHYROXINE SODIUM 		
					</strong><br><span class="contentTableReg">levothyroxine sodium anhydrous injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-647</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVOTHYROXINE SODIUM ANHYDROUS</strong> (LEVOTHYROXINE) </td>
<td class="formItem">LEVOTHYROXINE SODIUM ANHYDROUS</td>
<td class="formItem">200 ug  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-647-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202231</td>
<td class="formItem">06/24/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVOTHYROXINE SODIUM 		
					</strong><br><span class="contentTableReg">levothyroxine sodium anhydrous injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-648</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVOTHYROXINE SODIUM ANHYDROUS</strong> (LEVOTHYROXINE) </td>
<td class="formItem">LEVOTHYROXINE SODIUM ANHYDROUS</td>
<td class="formItem">500 ug  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-648-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202231</td>
<td class="formItem">06/24/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVOTHYROXINE SODIUM 		
					</strong><br><span class="contentTableReg">levothyroxine sodium anhydrous injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-649</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVOTHYROXINE SODIUM ANHYDROUS</strong> (LEVOTHYROXINE) </td>
<td class="formItem">LEVOTHYROXINE SODIUM ANHYDROUS</td>
<td class="formItem">100 ug  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-649-07</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202231</td>
<td class="formItem">06/24/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi USA, LLC</td>
<td class="formItem"></td>
<td class="formItem">023648251</td>
<td class="formItem">MANUFACTURE(63323-648, 63323-649, 63323-647)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1001cac8-bb9d-4abc-bc8f-c4c28dc3839e</div>
<div>Set id: ce990712-49c1-4f66-9ee4-c770e8ec394c</div>
<div>Version: 3</div>
<div>Effective Time: 20140205</div>
</div>
</div> <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
